MAP3K15 and type 2 diabetes mellitus: Of these, we highlight the association between a burden of protein-altering variants in MAP3K15 and both lower levels of haemoglobin A1c (7,551 carriers; effect = −0.085 s.d. units, 95% CI −0.100 to −0.073, P = 7.8 × 10−30), lower serum glucose (6,885 carriers; effect = −0.090 s.d. units, 95% CI −0.110 to −0.073, P = 1.7 × 10−25) and protection from type-2 diabetes (7,085 carriers; OR = 0.85, 95% CI 0.79 to 0.91, P = 2.8 × 10−6).